Department of Ophthalmology, Armed Forces Clinic, New Delhi, India.
Department of Ophthalmology, Military Hospital, Jammu, India.
Rom J Ophthalmol. 2024 Jul-Sep;68(3):268-273. doi: 10.22336/rjo.2024.49.
This study aims to renew the management of viral epidemic conjunctivitis by introducing a one-time, low-concentration ocular surface povidone-iodine (LOS-pI) wash.
Among the 3,002 patients screened, 1,328 with acute conjunctivitis were categorized into two groups. Group A (664 patients) underwent a 1% betadine wash in addition to the standard treatment protocol (Eye Lubricant + Moxifloxacin 0.5% eyedrops), while Group B (664 patients) followed the standard protocol alone. In cases of membranous conjunctivitis, manual membrane removal was performed. Treatment responses were observed daily for three days, followed by weekly assessments for two additional weeks.
Co-infection of adenovirus with enterovirus was found to be the main cause, often accompanied by staphylococcal superinfection. Group A showed complete resolution of conjunctival inflammation, with a remarkable 76.05% of patients experiencing improvement within an average of 2.6±0.51 days, in contrast to Group B's average of 7.5±1.1 days (p <0.05). Additionally, 13% of Group B patients with recalcitrant conjunctivitis significantly recovered following the 1% betadine wash. Complications (subconjunctival hemorrhage: 34.04%, superficial punctate keratitis: 6.02%) were more prevalent in Group B.
The authors hypothesized that a single wash with betadine is sufficient to reduce disease duration and prevent secondary infections and complications. The core strength of our study lies in its substantial sample size. To our knowledge, no similar previous research has been conducted, on such a larger scale.
Viral conjunctivitis brings discomfort, work absenteeism, and financial burden. A single low-concentration betadine wash expedites recovery and reduces complications in acute infective conjunctivitis. This approach significantly enhances patient outcomes and alleviates the socioeconomic impact of the condition.
本研究旨在通过引入一次性低浓度聚维酮碘（LOS-pI）冲洗液来更新病毒性流行结膜炎的管理方法。
在筛选的 3002 名患者中，1328 名急性结膜炎患者分为两组。A 组（664 例）在标准治疗方案（眼润滑剂+莫西沙星 0.5%滴眼剂）的基础上，加用 1%的聚维酮碘冲洗，B 组（664 例）仅采用标准方案。对于膜性结膜炎，采用手动膜清除。治疗反应每天观察 3 天，然后每周评估 2 周。
腺病毒与肠道病毒的合并感染是主要病因，常伴有葡萄球菌的继发感染。A 组结膜炎症完全消退，76.05%的患者在平均 2.6±0.51 天内明显改善，而 B 组的平均时间为 7.5±1.1 天（p<0.05）。此外，B 组 13%的难治性结膜炎患者在接受 1%聚维酮碘冲洗后显著恢复。并发症（结膜下出血：34.04%，浅层点状角膜炎：6.02%）在 B 组更为常见。
作者假设，单次使用聚维酮碘冲洗足以缩短疾病持续时间，预防继发感染和并发症。本研究的核心优势在于其较大的样本量。据我们所知，之前没有类似的大规模研究。
病毒性结膜炎会带来不适、缺勤和经济负担。单次低浓度聚维酮碘冲洗可加速急性感染性结膜炎的康复并减少并发症。这种方法显著改善了患者的结局，并减轻了疾病的社会经济影响。
